mTOR inhibitors show promising in vitro activity in bladder cancer and head and neck squamous cell carcinoma

Oncology Reports

Volumn 25, Issue 3, 2011, Pages 763-768

  Schedel, Fiona ^a   Pries, Ralph ^a   Thode, Beate ^a   Wollmann, Brigitte ^a   Wulff, Sandra ^a   Jocham, Dieter ^a   Wollenberg, Barbara ^a   Kausch, Ingo ^a,b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b Ammerland Klinik GmbH   (Germany)

Author keywords

Bladder cancer; Head and neck squamous cell carcinoma; mTOR; Temsirolimus

Indexed keywords

KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; SMALL INTERFERING RNA; TEMSIROLIMUS;

APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL STRAIN BHY; CELL STRAIN EJ28; CELL STRAIN PCI 1; CELL STRAIN PCI 13; CELL STRAIN RT 4; CELL STRAIN T24; CELL VIABILITY; DRUG MECHANISM; DRUG SCREENING; ENZYME INHIBITION; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSFECTION; HEAD AND NECK CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL PROLIFERATION; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; PROTEIN KINASE INHIBITORS; RNA, SMALL INTERFERING; SIROLIMUS; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 79551593447     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1146     Document Type: Article

References (17)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics. CA Cancer J Clin 59: 225-249, 2009.
2. ECO/OEC. European Cancer Observatory. International Agency for Cancer. Available from: http://eu-cancer.iarc.fr.; 2009.
3. Kausch I, Doehn C and Jocham D: Recent improvements in the detection and treatment of non-muscle-invasive bladder cancer. Expert Rev Anticancer Ther 6: 1301-1311, 2006.
4. Luce D, Guenel P, Leclerc A, Brugere J, Point D and Rodriguez J: Alcohol and tobacco consumption in cancer of the mouth, pharynx, and larynx: a study of 316 female patients. Laryngoscope 98: 313-316, 1988.
5. Chin D, Boyle GM, Theile DR, Parsons PG and Coman WB: Molecular introduction to head and neck cancer (HNSCC) carcinogenesis. Br J Plast Surg 57: 595-602, 2004. (Pubitemid 40348040)
6. Douglas WG, Tracy E, Tan D, Yu J, Hicks WL Jr, Rigual NR, Loree TR, Wang Y and Baumann H: Development of head and neck squamous cell carcinoma is associated with altered cytokine responsiveness. Mol Cancer Res 2: 585-593, 2004.
7. Pries R, Thiel A, Brocks C and Wollenberg B: Secretion of tumor-promoting and immune suppressive cytokines by cell lines of head and neck squamous cell carcinoma. In Vivo 20: 45-48, 2006.
8. Pries R and Wollenberg B: Cytokines in head and neck cancer. Cytokine Growth Factor Rev 17: 141-146, 2006.
9. Mann EA, Spiro JD, Chen LL and Kreutzer DL: Cytokine expression by head and neck squamous cell carcinomas. Am J Surg 164: 567-573, 1992.
10. Chen Z, Malhotra PS, Thomas GR, Ondrey FG, Duffey DC, Smith CW, Enamorado I, Yeh NT, Kroog GS, Rudy S, McCullagh L, Mousa S, Quezado M, Herscher LL and Van Waes C: Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 5: 1369-1379, 1999.
11. Woods KV, El-Naggar A, Clayman GL and Grimm EA: Variable expression of cytokines in human head and neck squamous cell carcinoma cell lines and consistent expression in surgical specimens. Cancer Res 58: 3132-3141, 1998. (Pubitemid 28335097)
12. Peponi E, Drakos E, Reyes G, et al: Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am J Pathol 169: 2171-2180, 2006.
13. Hudes GR, Berkenblit A, Feingold J, Atkins MB, Rini BI and Dutcher J: Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma. Semin Oncol 36 (Suppl. 3): 26-36, 2009.
14. Wullschleger S, Loewith R and Hall MN: TOR signaling in growth and metabolism. Cell 124: 471-484, 2006.
15. Mansure JJ, Nassim R, Chevalier S, Rocha J, Scarlata E and Kassouf W: Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer. Cancer Biol Ther 8: 2339-2347, 2009.
16. Vega F, Medeiros LF, Vasiliki V, et al: Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res 66: 6589-6597, 2006. (Pubitemid 44085614)
17. Liu Y, Hidayat S, Wen-hui S, Deng X, Yu D and Yu B: Expression and activity of mTOR and its substrates in different cell cycle phases and in oral squamous cell carcinomas of different malignant grade. Cell Biochem Funct 25: 45-53, 2007. (Pubitemid 46121783)